<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Exp Med</journal-id>
      <journal-title>The Journal of Experimental Medicine</journal-title>
      <issn pub-type="ppub">0022-1007</issn>
      <issn pub-type="epub">1540-9538</issn>
      <publisher>
        <publisher-name>The Rockefeller University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">10190897</article-id>
      <article-id pub-id-type="pmc">2193006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fas Gene Mutation in the Progression of Adult T Cell Leukemia </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Maeda</surname>
            <given-names>Takahiro</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamada</surname>
            <given-names>Yasuaki</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moriuchi</surname>
            <given-names>Ryozou</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sugahara</surname>
            <given-names>Kazuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsuruda</surname>
            <given-names>Kazuto</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joh</surname>
            <given-names>Tatsurou</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#x2016;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Atogami</surname>
            <given-names>Sunao</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsukasaki</surname>
            <given-names>Kunihiro</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tomonaga</surname>
            <given-names>Masao</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kamihira</surname>
            <given-names>Shimeru</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1e02c10N0x3e70010">&#x2021;</xref>
        </contrib>
      </contrib-group>
      <aff id="N0x1e02c10N0x3e70010">From the <label>*</label>Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute,  the <label>&#x2021;</label>Department of Laboratory Medicine, and the <label>&#xA7;</label>Department of Bacteriology, Nagasaki University  School of Medicine, Nagasaki 852-8102, Japan; and the <label>&#x2016;</label>Department of Laboratory Chemotherapy,  Aichi Cancer Center, Aichi 464-0021, Japan</aff>
      <author-notes>
        <fn>
          <p>Address correspondence to Takahiro Maeda, Department of Hematology and Molecular Medicine Unit,  Atomic Bomb Disease Institute, Nagasaki University School of Medicine, 1-7-1 Sakamoto-machi, Nagasaki  852-8102, Japan. Phone: 81-95-849-7380; Fax: 81-95-849-7538; E-mail: <email>tmaeda@net.nagasaki-u.ac.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>5</day>
        <month>4</month>
        <year>1999</year>
      </pub-date>
      <volume>189</volume>
      <issue>7</issue>
      <fpage>1063</fpage>
      <lpage>1071</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>12</month>
          <year>1998</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>1</month>
          <year>1999</year>
        </date>
      </history>
      <copyright-year>1999</copyright-year>
      <abstract>
        <p>Fas antigen (Apo-1/CD95) is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor receptor superfamily. Adult T cell leukemia (ATL) cells express Fas antigen  and show apoptosis after treatment with an anti-Fas monoclonal antibody. We established the  ATL cell line KOB, which showed resistance to Fas-mediated apoptosis, and found that KOB  expressed two forms of Fas mRNA, the normal form and a truncated form. The truncated  transcript lacked 20 base pairs at exon 9, resulting in a frame shift and the generation of a premature stop codon at amino acid 239. The same mutation was detected in primary ascitic cells  and peripheral blood cells. The mutation was not detected in lymph node cells, however, although all of the primary ATL cells were of the same clonal origin. A retroviral-mediated gene  transfer of the truncated Fas to Jurkat cells rendered the cells resistant to Fas-mediated apoptosis, suggesting a dominant negative interference mechanism. These results indicate that an  ATL subclone acquires a Fas mutation in the lymph nodes, enabling the subclone to escape  from apoptosis mediated by the Fas/Fas ligand system and proliferate in the body. Mutation of  the Fas gene may be one of the mechanisms underlying the progression of ATL.</p>
      </abstract>
      <kwd-group>
        <kwd>human &#x2009;T lymphotropic virus type I</kwd>
        <kwd>adult &#x2009;T cell leukemia</kwd>
        <kwd>apoptosis</kwd>
        <kwd>death domain</kwd>
        <kwd>CD95</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>The Fas antigen (Apo-1/CD95) is a 45-kD transmembrane protein that is a member of the TNF receptor  superfamily that can induce programmed cell death, i.e.,  apoptosis, when cross-linked by natural ligand or specific  antibodies. The human Fas antigen consists of 325 amino  acids with a single transmembrane domain, including signal  peptides. The extracellular domain is rich in cysteine residues and shows similarity to domains of human TNF receptor, human nerve growth factor receptor, and human B cell  antigen CD40 (<xref ref-type="bibr" rid="B1">1</xref>). The cytoplasmic domain (&#x223C;70 amino  acids), designated a death-signaling domain, is highly conserved between Fas and TNF receptor and is necessary  for the transduction of the apoptotic signal. A deletion of  15 amino acids from the COOH terminus enhances the Fas  antibody&#x2013;induced killing activity, whereas a further deletion abolishes its activity (<xref ref-type="bibr" rid="B2">2</xref>). Fas can exist as both a cell surface and a soluble protein, both of which are generated by  alternative splicing. While the cell surface Fas anchored by  a transmembrane domain induces apoptosis, soluble Fas protects cells from apoptosis (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>).</p>
    <p>The Fas/Fas ligand system of apoptosis appears to play an  important role in the normal development of T lymphocytes in the thymus by eliminating self-reactive lymphocytes (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Mutations in the Fas-encoding gene are responsible for the lymphoproliferative disorder in <italic>lpr</italic> and <italic>lpr<sup>cg</sup></italic>  mice, which are models of autoimmune disease. These mice  fail to eliminate self-reactive T lymphocytes, resulting in the  accumulation of a large number of nonmalignant CD4<sup>&#x2212;</sup>  CD8<sup>&#x2212;</sup> T lymphocytes in the lymph nodes and spleen (8&#x2013; 10). Similarly, several recent studies have identified function-ablating mutations of the Fas antigen in patients with a  human lupus&#x2013;like syndrome, designated congenital autoimmune lymphoproliferative syndrome (ALPS),<sup>1</sup> which is  identical to the <italic>lpr</italic> mouse phenotype and characterized by  lymphadenopathy, hypergammaglobulinemia, and autoimmunity. Interestingly, such mutations of the Fas gene inhibited  the Fas-mediated apoptosis by a dominant negative mechanism (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>).</p>
    <p>Adult T cell leukemia (ATL) is a mature helper T cell&#x2013; derived lymphoma (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>) caused by human T lymphotropic virus type I (HTLV-I; 17&#x2013;19). ATL is endemic to  the southwest area of Japan, the Caribbean Basin, West Africa, and the southern United States. Because the clinical  features of ATL patients are quite diverse, ATL is usually  classified into four subtypes&#x2014;acute, lymphoma, chronic,  and smoldering&#x2014;according to the criteria of Shimoyama  (<xref ref-type="bibr" rid="B20">20</xref>). Compared with non-Hodgkin's lymphoma patients,  ATL patients show significantly shorter terms of survival;  the median survival time is only 6.2 mo for an acute ATL  patient and 10.2 mo for patients with the lymphoma type  of ATL (<xref ref-type="bibr" rid="B21">21</xref>). The mechanism of chemoresistance of ATL  cells is not yet well understood. ATL cells express abundant  Fas antigen on their surfaces and undergo apoptosis induced  by an IgM anti-Fas mAb in vitro (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>), but ATL cells do  not show apparent apoptosis in vivo.</p>
    <p>Several Fas gene mutations have been reported in primary samples of myeloma, T cell lymphoblastic leukemia,  and ATL in patients other than our present patient (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>),  which suggests that Fas resistance contributes to the development of neoplasms. However, a functional analysis of the  detected mutant Fas gene in these diseases has not, to our  knowledge, been performed. In this study, we found that  the ATL cell line KOB carried a heterozygous Fas gene  mutation in exon 9 lacking a death-signaling domain and  acquired Fas resistance. The same mutation was detected in  the primary samples, ascites, and peripheral blood but not  in the lymph node. Moreover, by transfer of the mutant  Fas gene to Fas-sensitive Jurkat cells, we observed that the  aberrant Fas antigen functioned as a dominant negative interfering Fas signal.</p>
    <sec sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec disp-level="3">
        <title>Patient.</title>
        <p>A 72-yr-old man visited our hospital with complaints of low grade fever and systemic lymphadenopathy in April  1992. His white blood cell count was 1.2 &#xD7; 10<sup>10</sup>/liter, with 8%  abnormal lymphocytes. His lactic dehydrogenase (LDH) level and  serum calcium level were 4,400 IU/liter and 11 mg/dl, respectively. The diagnosis of acute type ATL was made hematocytologically and confirmed by the demonstration of monoclonal integration of HTLV-I proviral DNA in the peripheral blood and  lymph node mononuclear cells. The patient was administered 10  cycles of combination chemotherapy and discharged with a partial response. However, only 3 mo after the discontinuation of  chemotherapy, the patient was readmitted to our hospital with  massive ascites and an elevated LDH level (4312 IU/liter). Although combination chemotherapy was started again, the effect  was transient and the patient died of a systemic invasion of ATL  cells 3 mo after his second hospital admission.</p>
      </sec>
      <sec disp-level="3">
        <title>Clinical Samples and Cell Lines.</title>
        <p>Peripheral blood was drawn  several times during the patient's hospital stays. A lymph node  was biopsied during his first admission, and ascites were obtained  during his second admission. All materials were obtained after informed consent. Mononuclear cells were separated from the samples by centrifugation over a Ficoll gradient and cryopreserved  until use. The ATL cell line KOB was established from the patient's ascitic ATL cells. The other three ATL cell lines (KK1,  ST1, and SO4) used for the present study were also of primary  ATL cell origin established from the respective ATL patients (<xref ref-type="bibr" rid="B29">29</xref>,  <xref ref-type="bibr" rid="B30">30</xref>). All ATL cell lines were dependent on exogenously added IL-2  and were maintained in RPMI 1640 supplemented with 10% FBS  and 0.5 U/ml IL-2.</p>
      </sec>
      <sec disp-level="3">
        <title>Flow Cytometric Analysis for Membrane Fas.</title>
        <p>Membrane Fas was  examined by flow cytometry as described previously using a Cytron  flow cytometer (Ortho; 31). The resulting histograms (see Fig. <xref ref-type="fig" rid="F1">1</xref>)  correspond to the cell number (y-axis) versus fluorescence intensity (x-axis) plotted on a logarithmic scale. </p>
      </sec>
      <sec disp-level="3">
        <title>RNA Extraction and Reverse Transcriptase (RT)-PCR.</title>
        <p> Total  RNA was prepared from the cell lines and clinical samples using  ISOGEN (Wako). After the removal of DNA contamination using a MassageClean&#x2122; kit (GenHunter Corp.), cDNA was made  from 1 &#x3BC;g of total RNA using an RNA PCR core kit (<named-content content-type="company" xlink:href="perkin">Perkin  Elmer</named-content>) according to the manufacturer's protocol. Oligo dT primers were used to prime the first strand synthesis for each of the reactions. Four oligonucleotide primer pairs were designed to amplify the full length coding region of Fas according to the method  of Cheng et al. (<xref ref-type="bibr" rid="B3">3</xref>). The reaction conditions were 35 cycles of  94&#xB0;C for 70 s, 60&#xB0;C for 30 s, and 72&#xB0;C for 60 s (for full length  Fas) or 30 cycles of 95&#xB0;C for 60 s, 54&#xB0;C for 60 s, and 72&#xB0;C for 60 s  (for Fas I, Fas II, and Fas III; Table <xref ref-type="table" rid="TI">I</xref>). These amplified products  were electrophoretically separated and visualized on an ethidium  bromide&#x2013;stained 2% agarose gel or a silver-stained 12.5% acrylamide gel using a GenePhor electrophoresis unit (<named-content content-type="company" xlink:href="pharmacia">Pharmacia Biotech</named-content>). </p>
      </sec>
      <sec disp-level="3">
        <title>Subcloning and Sequencing.</title>
        <p>We cloned the RT-PCR products  of full length Fas and Fas III derived from KOB or clinical samples into the pCR&#x2122;II vector using a TA cloning kit (Invitrogen  Corp.). All sequencing experiments were performed using an  AutoRead&#x2122; sequencing kit designed for an ALF&#x2122; DNA sequencer (<named-content content-type="company" xlink:href="pharmacia">Pharmacia Biotech</named-content>).</p>
      </sec>
      <sec disp-level="3">
        <title>Construction of Retroviral Vectors and Transfection.</title>
        <p>The truncated  full length Fas cDNA of KOB origin was inserted into the retroviral vector LXSN. This vector contains Moloney murine sarcoma virus&#x2013;derived long terminal repeats and a neomycin resistance gene under the control of simian virus 40 early promoter.  The recombinant retroviral vector LdelSN was purified using an  EndoFree Plasmid Maxiprep kit (Qiagen) and was transfected  into the ecotropic packaging cell line &#x3C8;2 using FuGENE&#x2122;6  transfection reagent (<named-content content-type="company" xlink:href="boehringer">Boehringer Mannheim</named-content>). After a 48-h culture  in DMEM, the transient retroviral supernatant was used to transduce the amphotropic packaging cell line PA317. The PA317  cells infected with recombinant retroviruses were cultured in  DMEM for 48 h and selected with 0.8 mg/ml G-418. Supernatants of PA317 cells producing amphotropic retroviruses were  used to transduce Jurkat cells. The transduced Jurkat cells were selected in RPMI 1640 containing 1 mg/ml G-418 and were cloned  by the colony formation method on methylcellulose-containing  culture plates.</p>
      </sec>
      <sec disp-level="3">
        <title>Detection of HTLV-I Proviral DNA and TCR Gene Rearrangement Profile.</title>
        <p>The integration site(s) of HTLV-I proviral DNA  and TCR gene rearrangement were examined with a Southern  blot hybridization assay using probes for the pX region of  HTLV-I and TCR C&#x3B2;1 according to the described method (<xref ref-type="bibr" rid="B24">24</xref>,  <xref ref-type="bibr" rid="B32">32</xref>). In brief, the high molecular DNA samples (10 &#x3BC;g) extracted  from the cell lines and clinical samples were digested with restriction enzymes and size fractionated on 0.7% agarose gels. They  were then denatured and transferred onto positively charged nitrocellulose membranes (<named-content content-type="company" xlink:href="boehringer">Boehringer Mannheim</named-content>) and hybridized  to digoxigenin-labeled probes. Thereafter, the blots were washed  at appropriate stringency and treated with an anti-digoxigenin  antibody conjugated with alkaline phosphatase (<named-content content-type="company" xlink:href="boehringer">Boehringer Mannheim</named-content>), and the alkaline phosphatase was changed to a light signal  by CDP-Star&#x2122; (<named-content content-type="company" xlink:href="boehringer">Boehringer Mannheim</named-content>) and exposed to film.  The restriction enzymes used were EcoRI and PstI for HTLV-I  proviral DNA and EcoRV and BamHI for TCR &#x3B2; chain gene  rearrangement.</p>
      </sec>
      <sec disp-level="3">
        <title>Detection of Apoptosis.</title>
        <p>In the process of early apoptosis, cells  express phosphatidylserine on the outer leaflet of the cell surface  membrane and consequently bind annexin V. Cell lines cultured  with or without IgM anti-Fas mAb at a final concentration of  1 &#x3BC;g/ml were examined for annexin V binding by flow cytometry at several time points after culture using an annexin V&#x2013;FITC  kit (Takara Shuzo Co.) according to the manufacturer's protocol.  A DNA fragmentation analysis was also performed using the same  samples and an apoptosis ladder detection kit (Wako).</p>
      </sec>
      <sec disp-level="3">
        <title>Cell Proliferation Assay.</title>
        <p>First, 10<sup>5</sup> cells/100 &#x3BC;l RPMI 1640  supplemented with 10% FCS were cultured with or without  1 &#x3BC;g/ml of IgM anti-Fas mAb in 96-well tissue culture plates for 7,  16, 24, or 32 h, and proliferation status was estimated by measuring  the conversion of MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) into  water-soluble formazan (CellTiter 96TMAQueous; <named-content content-type="company" xlink:href="promega">Promega</named-content>)  according to the manufacturer's protocol. All experiments were  performed in triplicate.</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec disp-level="4">
        <title>Expression of Fas Antigen on Cell Lines and Response to IgM  anti-Fas mAb.</title>
        <p>Four ATL cell lines were analyzed for the  expression of Fas antigen (Apo-1/CD95) by flow cytometry using an IgG anti-Fas mAb. As shown in Fig. <xref ref-type="fig" rid="F1">1</xref>, all four  ATL cell lines (KK1, KOB, ST1, and SO4) and Jurkat cells  expressed Fas antigen, whereas the cell line K562 used as a  negative control did not. These cell lines were cultured  with 1 &#x3BC;g/ml IgM anti-Fas mAb, and cell proliferation status  was examined. The results are expressed as a value against  the control cells cultured without mAb. As shown in Fig.  <xref ref-type="fig" rid="F2">2</xref> A, after a 24-h culture with the mAb, the proliferation of  KK1, SO4, and ST1 cells was significantly suppressed: to  16.8, 7.7, and 10.8% of the control level, respectively. In  contrast, the KOB and K562 cells were not affected. To  confirm that suppression was due to apoptosis, we performed a flow cytometric analysis of annexin V binding and  a DNA fragmentation assay for the early and late phases of  apoptosis, respectively. In Jurkat cells, an annexin V&#x2013;binding  cell population appeared 3 h after treatment with IgM anti-Fas mAb (14%), and the population was further increased  at 5 h (50.1%). In contrast, no annexin V&#x2013;binding cell population appeared in KOB cells (Fig. <xref ref-type="fig" rid="F2">2</xref> B). Likewise, the  other ATL cell lines (KK1, SO4, and ST1) exhibited annexin V binding but K562 cells did not (data not shown).  Supporting the results of annexin V binding, DNA ladder  formation appeared in the three ATL cell lines (KK1, SO4,  and ST1) but not in KOB and K562 cells after 3 h of culture (data not shown). These results prompted us to examine the mechanism of Fas resistance in KOB cells. </p>
      </sec>
      <sec disp-level="4">
        <title>RT-PCR and Sequencing of Fas Gene.</title>
        <p>To investigate the  Fas mRNA, four primer pairs were designed to cover its full  length coding region. These PCR reactions were named  Fas I, Fas II, and Fas III (Table <xref ref-type="table" rid="TI">I</xref>). The expected size of the  bands in Fas I and Fas III was 336 and 344 bp, respectively.  Fas II was expected to show two bands (339 and 276 bp)  generated by alternative splicing; the larger PCR product  corresponds to the membrane form, and the smaller product corresponds to the soluble form of Fas mRNA, which  is 63 bp shorter than the membrane form. Irregardless of  the samples, only the expected bands were observed in the  Fas I and Fas II reactions. In contrast, in the Fas III reaction  of KOB cells, a distinct  smaller product was observed in  addition to the expected 344-bp band (Fig. <xref ref-type="fig" rid="F3">3</xref> A). The sequencing analysis of full length RT-PCR products of KOB  cells showed two transcripts, the normal form and a truncated form. The truncated transcript lacked 20 bp (from nucleotide [nt] 686 to nt 705, nucleotide numbers that correspond to those reported by Itoh et al. [1]) at exon 9 within  the cytoplasmic death-signaling domain. The frame shift  caused by the deletion generated a premature stop codon at  amino acid 239, resulting in the production of aberrant Fas  antigen which lacked the entire death-signaling domain  (Fig. <xref ref-type="fig" rid="F3">3</xref> B). </p>
      </sec>
      <sec disp-level="4">
        <title>Origin of KOB Cell Line.</title>
        <p>Hematocytologically, characteristic ATL cells with deeply indented or lobulated nuclei  and relatively scanty basophilic cytoplasm were observed in  the peripheral blood, lymph node, and ascites of our patient. We examined the integration pattern of HTLV-I  proviral DNA and TCR &#x3B2; chain gene rearrangement profiles by Southern blot analysis to determine the origin of  KOB cells. As shown in Fig. <xref ref-type="fig" rid="F4">4</xref> A, one monoclonal band  was observed at the same position in all primary samples  when cellular DNAs was digested with EcoRI or PstI. In  addition, multiple bands other than the original band of the  primary samples were observed in KOB cells, suggesting  the superinfection of HTLV-I in vitro. In the TCR &#x3B2;  chain gene rearrangement profile, the same rearranged band  (Fig. <xref ref-type="fig" rid="F4">4</xref> B, arrowhead R) was observed in all samples including KOB when the cellular DNA was digested with BamHI.  The loss of the germline band at 12 kb was observed in all  but one sample (peripheral blood) when the cellular DNA  was digested with EcoRV, indicating the deletion of the  TCR C&#x3B2; 1 locus in this clone (Fig. <xref ref-type="fig" rid="F4">4</xref> B). The germline band  at 12 kb observed in peripheral blood indicates the presence  of normal non-T cells. These results suggest that KOB cells  originated from the primary ATL cells. We therefore investigated whether the primary samples also expressed the truncated Fas gene. We performed an RT-PCR analysis of Fas  III in all primary samples. Interestingly, although the same  smaller product observed in KOB cells was detected in peripheral blood ATL cells and ascitic ATL cells, no such product was detected in lymph node ATL cells (Fig. <xref ref-type="fig" rid="F4">4</xref> C). The  sequence analysis of these products disclosed that the clinical  samples from peripheral blood and ascites had the same Fas  gene mutation observed in KOB cells. No such mutation  was observed in the lymph node cells (data not shown). </p>
      </sec>
      <sec disp-level="4">
        <title>Retroviral-mediated Transfer of the Mutant Fas Gene.</title>
        <p> To  confirm that the mutant Fas gene is responsible for Fas resistance in KOB cells, we constructed the retroviral vector  LdelSN containing the truncated Fas cDNA and transferred  it into Jurkat cells. The successful transfer of the gene in  G418-resistant cells was confirmed by RT-PCR of Fas III  and neomycin resistance gene&#x2013;specific sequences and by  sequencing analysis. RT-PCR analysis of Fas III showed  two transcripts in all LdelSN-transduced Jurkat cell clones  (RJ-9, RJ-11, and RJ-14) but only normal transcript in  wild-type and LXSN-transduced Jurkat cell clones (LX-1,  LX-2, and LX-3; Fig. <xref ref-type="fig" rid="F5">5</xref> A). We performed a sequencing  analysis of the RT-PCR products from transduced Jurkat  cells and verified the expression of transferred Fas gene  (data not shown). </p>
        <p>The LXSN- and LdelSN-transduced Jurkat cells were  assayed for Fas sensitivity. The flow cytometric analysis of  annexin V binding showed that the LXSN-transduced Jurkat cell clone LX-2 demonstrated a marked increase of the  annexin V&#x2013;binding cell population of 3.3% at 0 h to 56.8%  at 3 h after treatment with IgM anti-Fas mAb, and the population increased further to 77.2% at 5 h. In contrast, the  LdelSN-transduced Jurkat cell clone RJ-14 showed no such  increase (Fig. <xref ref-type="fig" rid="F5">5</xref> B). Using CellTiter 96TMAQueous, the proliferation status was evaluated at several time points of culture with 1 &#x3BC;g/ml of IgM anti-Fas mAb. The proliferation  of the LXSN-transduced Jurkat cell clones LX-1 and LX-3  was significantly suppressed to 37.6 and 33.4% of the control level, respectively, but the LdelSN-transduced Jurkat  cell clones RJ-9, RJ-11, and RJ-14 were not affected (Fig.  <xref ref-type="fig" rid="F5">5</xref> C). The characteristic features of apoptosis, i.e., reduction  of cell size, condensation and aggregation of nuclear chromatin, and nuclear fractionation were observed in wild-type  Jurkat cells and LXSN-transduced Jurkat cell clones but not  in LdelSN-transduced Jurkat cell clones (Fig. <xref ref-type="fig" rid="F6">6</xref>). </p>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Most ATL cells express abundant Fas antigen on their  surfaces and show apoptosis in a short term culture with  IgM anti-Fas mAb (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B33">33</xref>). We reported that ATL  cells from all but 2 of 33 patients expressed Fas antigen, and  the Fas<sup>&#x2212;</sup> ATL cells were resistant to apoptosis (<xref ref-type="bibr" rid="B34">34</xref>). Differences in Fas expression seem to be correlated with subtypes  of ATL; the level of Fas expression was higher in chronic  type than in acute type ATL patients and was inversely correlated with serum LDH activity (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). These results  may indicate that the Fas/Fas ligand system plays a critical  role in elimination of ATL cells.</p>
      <p>Fas gene mutations were recently reported in some malignancies. 7 cases of malignancy with Fas gene mutations were  detected in 48 multiple myeloma patients by the RT-PCR  method and a single-stranded conformation polymorphism  (SSCP) analysis. All of these mutations were point mutations in the cytoplasmic region, and two of them were  silent mutations (<xref ref-type="bibr" rid="B26">26</xref>). 2 cases of Fas gene mutations were  found among 81 childhood T-lineage acute lymphoblastic  leukemia patients using PCR and single-stranded conformation polymorphism analysis as the screening methods;  one case was a heterozygous point mutation in exon 3, and  another case was a homozygous alteration in the promoter  region (<xref ref-type="bibr" rid="B27">27</xref>). The 3 cases of Fas gene mutations detected  among 47 ATL patients by an RNase protection assay were  a 5-bp deletion in exon 2, a 1-bp insertion in exon 2, and a  loss of exon 4. Two silent point mutations were also observed (<xref ref-type="bibr" rid="B28">28</xref>). Rearrangement or allelic loss of Fas gene were  also reported in 5 of 70 patients with non-Hodgkin's lymphoma: 3 cases of allelic loss and 2 cases of rearrangement  (<xref ref-type="bibr" rid="B35">35</xref>). According to these reports, it is likely that Fas gene  mutations, including silent mutations, occur at relatively  low but diverse frequencies, &#x223C;2.5&#x2013;14.6%, and are consistently detected in lymphoid malignancies, suggesting an association between Fas mutation and disease progression in  lymphoid malignancies. However, a functional analysis of  the aberrant Fas was not performed in any of the above  studies.</p>
      <p>In many receptor and ligand systems such as epidermal  growth factor, fibroblast growth factor, and platelet-derived  growth factor &#x3B2;, dimerizations of receptor subunits appear  to be essential for signal transduction. The truncated forms  of these receptors suppress the response of wild-type receptor by heterodimerization (<xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B41">41</xref>). Analysis of the crystal  structure of TNF receptor&#x2013;TNF-&#x3B2; complex demonstrated  that three TNF receptor molecules symmetrically bound to  TNF-&#x3B2; trimer (<xref ref-type="bibr" rid="B42">42</xref>). The human soluble Fas ligand also  forms homotrimers (<xref ref-type="bibr" rid="B43">43</xref>). It has been reported that the trimerization of the death-signaling domain within the cytoplasmic region of Fas is essential for signal transduction in  the process of Fas-mediated apoptosis (<xref ref-type="bibr" rid="B44">44</xref>). Therefore, it is  likely that KOB cells prevented apoptosis by an expression  of function-ablating Fas antigen on their surfaces similar to  the expression on lymphocytes of ALPS patients. The truncated Fas antigen, which lacks the entire death-signaling  domain, may behave as a decoy receptor and interfere with  the trimerization of normal Fas in a competitive manner,  resulting in the impairment of signal transduction.</p>
      <p>To test this hypothesis, we constructed the retroviral  vector LdelSN containing the truncated Fas cDNA and  transferred it into Jurkat cells, which are sensitive to IgM  anti-Fas mAb. The resulting Jurkat cells became almost  completely resistant to IgM anti-Fas mAb, suggesting that  heterotrimers between the truncated Fas and normal Fas,  which was endogenously expressed in Jurkat cells, did not  transduce the apoptotic signal. Although the pathological  role of aberrant Fas antigen has been demonstrated in ALPS  by the method of transient gene transfer, no such trial has  been performed in neoplasms. The present study is, to our  knowledge, the first that has successfully demonstrated the  dominant negative inhibition of apoptosis by a stably transfected cell line.</p>
      <p>More interestingly, the mutated Fas gene observed in  KOB cells was not detected in lymph node ATL cells, although a Southern blot analysis indicated that all of the primary ATL cells and KOB cells were of the same cell origin.  These results indicate that ATL cells developed in the  lymph nodes have acquired Fas gene mutation, and the  subclone with the mutation spread to the whole body, escaping elimination by the Fas/Fas ligand system. It has been  suspected that HTLV-I&#x2013;infected T lymphocytes proliferate  in lymph nodes at an early phase of malignant alteration  and gradually progress from the carrier type to the smoldering, chronic, and acute types of ATL. Based on a statistical  analysis of the age distribution of ATL patients, the lymphomagenesis of ATL was proposed to consist of at least  five steps (<xref ref-type="bibr" rid="B45">45</xref>). Although abnormalities in tumor suppressor  genes such as p53, p15, or p16 are supposed to be one of  the steps for progression of ATL (<xref ref-type="bibr" rid="B46">46</xref>&#x2013;<xref ref-type="bibr" rid="B48">48</xref>), the precise mechanism of lymphomagenesis remains unknown. Function-ablating Fas mutations might be involved in the multistep  lymphomagenesis of ATL.</p>
      <p>It is, however, unlikely that the Fas gene mutation alone  leads to a malignant transformation. Fas-deficient lpr mice  do not develop malignancies, and patients with ALPS have  rarely developed malignancies. Interestingly, lpr mice,  which constitutively express the L-myc transgene in the  lymphoid lineage, show an accelerated formation of T and  B cell lymphomas, but the L-myc transgene alone did not  produce such an acceleration in normal mice (<xref ref-type="bibr" rid="B49">49</xref>). It has  been reported that mice deficient in both T cells and Fas  gene develop B cell lymphoma (<xref ref-type="bibr" rid="B50">50</xref>). These reports suggest  that lymphomagenesis requires other events besides the loss  of Fas receptor function. In the present investigation, it  seems feasible that lymph node ATL cells with some genetic abnormalities that are crucial for the development of  ATL progressed to a more aggressive form by acquiring a  Fas gene mutation.</p>
      <p>In conclusion, we found a function-ablating Fas gene  mutation in an ATL cell line (KOB) and its primary ATL  cells. By retrovirus-mediated gene transfer, we verified that  the aberrant Fas interfered with apoptosis by a dominant  negative mechanism. The absence of the Fas gene mutation  in lymph node ATL cells suggests that this mutation is a  late event that occurs after the development of ATL and  that the ATL subclone with Fas mutation escaped from the  apoptosis mediated by the Fas/Fas ligand system and spread  to the entire body of the patient. Abnormality of Fas function may be one of the important steps in the progression  of ATL.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="display-objects">
      <title>Figures and Tables</title>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p>Flow cytometric analysis of Fas antigen. All cell lines but one  (K562) expressed the Fas antigen on their surfaces. Cells were incubated  with IgG anti-Fas mAb (solid line) or control mAb (dashed line).</p>
        </caption>
        <graphic xlink:href="JEM982105.f1"/>
      </fig>
      <table-wrap position="float" id="TI">
        <label>Table I</label>
        <caption>
          <p>Fas Primers </p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th>Gene segment</th>
              <th/>
              <th>Primer sequence</th>
              <th/>
              <th>PCR product</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">Fas full length</td>
              <td align="left"/>
              <td align="left">Sense: &#x2003;&#x2002;&#x2009;5&#x2032;-CACTTCGGAGGATTGCTCAACA</td>
              <td align="left"/>
              <td align="left"/>
            </tr>
            <tr>
              <td align="left"/>
              <td align="left"/>
              <td align="left">Antisense: 5&#x2032;-TATGTTGGCTCTTCAGCGCTA</td>
              <td align="left"/>
              <td align="left">1,167 bp (nt. 170&#x2013;1336)</td>
            </tr>
            <tr>
              <td align="left">Fas I</td>
              <td align="left"/>
              <td align="left">Sense: &#x2003;&#x2002;&#x2009;5&#x2032;-ATGCTGGGCATCTGGACCCT</td>
              <td align="left"/>
              <td align="left"/>
            </tr>
            <tr>
              <td align="left"/>
              <td align="left"/>
              <td align="left">Antisense: 5&#x2032;-GCCATGTCCTTCATCACACAA</td>
              <td align="left"/>
              <td align="left">336 bp (nt. 195&#x2013;530)</td>
            </tr>
            <tr>
              <td align="left">Fas II</td>
              <td align="left"/>
              <td align="left">Sense: &#x2003;&#x2002;&#x2009;5&#x2032;-CATGGCTTAGAAGTGGAAAT</td>
              <td align="left"/>
              <td align="left"/>
            </tr>
            <tr>
              <td align="left"/>
              <td align="left"/>
              <td align="left">Antisense: 5&#x2032;-ATTTATTGCCACTGTTTCAGG</td>
              <td align="left"/>
              <td align="left">339 bp (nt. 525&#x2013;863)</td>
            </tr>
            <tr>
              <td align="left">Fas III</td>
              <td align="left"/>
              <td align="left">Sense: &#x2003;&#x2002;&#x2009;5&#x2032;-AAATTTATCTGATGTTGACT</td>
              <td align="left"/>
              <td align="left"/>
            </tr>
            <tr>
              <td align="left"/>
              <td align="left"/>
              <td align="left">Antisense: 5&#x2032;-TCTAGACCAAGCTTTGGATTTC</td>
              <td align="left"/>
              <td align="left">344 bp (nt. 860&#x2013;1203)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>cDNA nucleotide numbers correspond to those reported by Itoh et al. (<xref ref-type="bibr" rid="B1">1</xref>).    &#xA0;</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig position="float" id="F2">
        <label>Figure 2</label>
        <caption>
          <p>Response to IgM anti-Fas mAb. (A) Proliferation status after treatment with IgM anti-Fas mAb. Results are expressed as values against the  control cells cultured without mAb. The proliferation of three ATL cell lines, SO4 (open circle), KK1 (filled circle), and ST1 (filled triangles) were  strongly suppressed to 7.7, 16.8, and 10.8% of the control level, respectively, whereas KOB (open square) and K562 (filled square) cells were not affected.  Data are the mean &#xB1; SD from three independent experiments. (B) Flow cytometric detection of annexin V binding. Jurkat cells clearly exhibited annexin V binding 3 h after treatment with IgM anti-Fas mAb (14%), and the binding population was further increased at 5 h (50.1%), whereas no annexin  V binding was observed in KOB cells.</p>
        </caption>
        <graphic xlink:href="JEM982105.f2a"/>
        <graphic xlink:href="JEM982105.f2b"/>
      </fig>
      <fig position="float" id="F3">
        <label>Figure 3</label>
        <caption>
          <p>Detection of Fas gene mutation. (A) RT-PCR analysis of human Fas mRNA. The expected bands for Fas I and Fas III were 336 and 344  bp, respectively. Due to alternative splicing, two expected bands (339 bp and 276 bp) were detected in Fas II analysis. No difference in Fas I and Fas II  was observed between samples. For Fas III, in addition to the expected 344-bp band, a distinct smaller product was observed in lane 4, which corresponds  to KOB cells. Lanes 1&#x2013;4 correspond to the ATL cell lines SO4, ST1, KK1, and KOB, respectively. Lanes 5 and 6 correspond to freshly isolated ATL  cells. Lane 7 is a normal control. (B) Sequencing analysis of RT-PCR products of KOB cells. The aberrant transcript that lacks 20 bp (from nucleotide  686 to nucleotide 705, numbers that correspond to those reported by Itoh et al. [1]) at exon 9 was detected. The frame shift caused by this deletion generates a premature stop codon at amino acid 239.</p>
        </caption>
        <graphic xlink:href="JEM982105.f3a"/>
        <graphic xlink:href="JEM982105.f3b"/>
      </fig>
      <fig position="float" id="F4">
        <label>Figure 4</label>
        <caption>
          <p>Origin of KOB cells. (A) Southern blot analysis of HTLV-I proviral DNA. A monoclonal band is observed at the same position in all primary samples. Multiple extra bands are observed in lanes 4 and 8, which correspond to KOB cells, suggesting the superinfection of HTLV-I in vitro. Lanes  1 and 5, peripheral blood ATL cells; lanes 2 and 6, lymph node ATL cells; lanes 3 and 7, ascitic ATL cells; lanes 4 and 8, KOB cells; M, size marker. (B)  TCR C&#x3B2; gene rearrangement profile. The same rearranged bands (arrowhead R) were observed in all samples digested with BamHI. With EcoRV digestion, the loss of the germline band at 12 kb is observed in lanes 8&#x2013;10. The germline band at 12 kb in lane 8 indicates the presence of some non-T cells  in the peripheral blood. Lanes 1 and 7, human placenta; lanes 2 and 8, peripheral blood ATL cells; lanes 3 and 9, lymph node ATL cells; lanes 4 and 10,  ascitic ATL cells; lanes 5, 6, 11, and 12, KOB cells; G, germline bands. (C) RT-PCR analysis of Fas III reaction. In addition to the normal 344-bp band  (arrow 1), the same distinct smaller products (arrow 2) are observed in lanes 2, 4, and 5. Lane 1, Jurkat cells; lane 2, KOB cells; lane 3, lymph node ATL  cells; lane 4, peripheral blood ATL cells; lane 5, ascitic ATL cells; lane 6, peripheral blood mononuclear cells from a healthy volunteer. M, size marker.</p>
        </caption>
        <graphic xlink:href="JEM982105.f4a"/>
        <graphic xlink:href="JEM982105.f4b"/>
        <graphic xlink:href="JEM982105.f4c"/>
      </fig>
      <fig position="float" id="F5">
        <label>Figure 5</label>
        <caption>
          <p>Retroviral-mediated gene transfer and response to IgM anti-Fas mAb. (A)  RT-PCR analysis in Fas III reaction. All LdelSN-transduced Jurkat cell clones (lane 5, RJ-9;  lane 6, RJ-11; lane 7, RJ-14) expressed two transcripts corresponding to the normal Fas  (arrow 1) and truncated Fas (arrow 2), but only the normal transcript was detected in wild-type (lane 1) and all LXSN-transduced Jurkat cell clones (lane  2, LX-1; lane 3, LX-2; lane 4, LX-3); M, size marker. (B) Flow cytometric detection of annexin V binding. A marked increase in the annexin V&#x2013;binding  cell population was observed in the LXSN-transduced Jurkat cell clone LX-2 after a 3-h culture with mAb (3.3% at 0 h, 3.1% at 1 h, 56.8% at 3 h, and  77.2% at 5 h). No increase was detected in the LdelSN-transduced Jurkat cell clone RJ-14. (C) Evaluation of proliferation status. The proliferation of  LXSN-transduced Jurkat cell clones LX-1 (filled square) and LX-3 (filled circle) was significantly suppressed to 37.6 and 33.4% of the control level, respectively, but the LdelSN-transduced Jurkat cell clones RJ-9 (open circle), RJ-11 (open triangle), and RJ-14 (open square) were not affected by mAb.  Data are the mean &#xB1; SD from three independent experiments.</p>
        </caption>
        <graphic xlink:href="JEM982105.f5a"/>
        <graphic xlink:href="JEM982105.f5b"/>
        <graphic xlink:href="JEM982105.f5c"/>
      </fig>
      <fig position="float" id="F6">
        <label>Figure 6</label>
        <caption>
          <p>Morphological changes after treatment with mAb. May-Gr&#xFC;nwald Giemsa staining at an original magnification of 1000 is shown. The characteristic features of apoptosis, including the reduction of cell size, condensation and aggregation of nuclear chromatin, and nuclear fractionation, were  observed in wild-type Jurkat cells and LXSN-transduced Jurkat cell clones; no morphological change was observed in the LdelSN-transduced Jurkat cell  clone.</p>
        </caption>
        <graphic xlink:href="JEM982105.f6"/>
      </fig>
    </sec>
    <ack>
      <p>We are grateful to Dr. T. Fujimoto, Mr. K. Nohda, Miss T. Hayashi, and Miss N. Dateki for their excellent  technical assistance and to Dr. A. Mizogami, Dr. D. Imanishi, and Dr. Y. Imaizumi for their critical advice.  IL-2 was kindly provided by Takeda Pharmaceutical Co.</p>
      <p>This work was supported by research grants from the Japanese Ministry of Education (Y. Yamada,  10670956 and 07671214; and S. Kazuyuki, 06280117).</p>
    </ack>
    <glossary>
      <title>Abbreviations used in this paper</title>
      <def-list>
        <def-item>
          <term>ALPS</term>
          <def>
            <p>autoimmune lymphoproliferative  syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>ATL</term>
          <def>
            <p>adult T cell leukemia</p>
          </def>
        </def-item>
        <def-item>
          <term>HTLV-I</term>
          <def>
            <p>human T lymphotrophic virus type I</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p>lactic dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>nt</term>
          <def>
            <p>nucleotide</p>
          </def>
        </def-item>
        <def-item>
          <term>RT</term>
          <def>
            <p>reverse transcriptase</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itoh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yonehara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yonehara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mizushima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sameshima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hase</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis</article-title>
          <source>Cell</source>
          <year>1991</year>
          <volume>66</volume>
          <fpage>233</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">1713127</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itoh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen</article-title>
          <source>J Biol Chem</source>
          <year>1993</year>
          <volume>268</volume>
          <fpage>10932</fpage>
          <lpage>10937</lpage>
          <pub-id pub-id-type="pmid">7684370</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Brauer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kiefer</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Mountz</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule</article-title>
          <source>Science</source>
          <year>1994</year>
          <volume>263</volume>
          <fpage>1759</fpage>
          <lpage>1762</lpage>
          <pub-id pub-id-type="pmid">7510905</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cascino</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fiucci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Papoff</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ruberti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Three functional soluble forms of the human apoptosis- inducing Fas molecule are produced by alternative splicing</article-title>
          <source>J  Immunol</source>
          <year>1995</year>
          <volume>154</volume>
          <fpage>2706</fpage>
          <lpage>2713</lpage>
          <pub-id pub-id-type="pmid">7533181</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Papoff</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cascino</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Eramo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Starace</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Ruberti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>An N-terminal domain shared by Fas/ Apo-1 (CD95) soluble variants prevents cell death in vitro</article-title>
          <source>J  Immunol</source>
          <year>1996</year>
          <volume>156</volume>
          <fpage>4622</fpage>
          <lpage>4630</lpage>
          <pub-id pub-id-type="pmid">8648105</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Ramsdell</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Alderson</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Fas and FasL in the homeostatic regulation of immune responses</article-title>
          <source>Immunol Today</source>
          <year>1995</year>
          <volume>16</volume>
          <fpage>569</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="pmid">8579749</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis by death factor</article-title>
          <source>Cell</source>
          <year>1997</year>
          <volume>88</volume>
          <fpage>355</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">9039262</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watanabe-Fukunaga</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brannan</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Copeland</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis</article-title>
          <source>Nature</source>
          <year>1992</year>
          <volume>356</volume>
          <fpage>314</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="pmid">1372394</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adachi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Watanabe-Fukunaga</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1993</year>
          <volume>90</volume>
          <fpage>1756</fpage>
          <lpage>1760</lpage>
          <pub-id pub-id-type="pmid">7680478</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Fas and Fas ligand: lpr and gld mutations</article-title>
          <source>Immunol Today</source>
          <year>1995</year>
          <volume>16</volume>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">7533498</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Straus</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Dale</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Strober</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lenardo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Puck</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome</article-title>
          <source>Cell</source>
          <year>1995</year>
          <volume>81</volume>
          <fpage>935</fpage>
          <lpage>946</lpage>
          <pub-id pub-id-type="pmid">7540117</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Le Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hivroz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Debatin</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Villartay</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity</article-title>
          <source>Science</source>
          <year>1995</year>
          <volume>268</volume>
          <fpage>1347</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">7539157</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bettinardi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brugnoni</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Quiros-Roldan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Malagoli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>La Grutta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Correra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>902</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="pmid">9028321</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drappa</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vaishnaw</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Elkon</surname>
              <given-names>KB</given-names>
            </name>
          </person-group>
          <article-title>Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>335</volume>
          <fpage>1643</fpage>
          <lpage>1649</lpage>
          <pub-id pub-id-type="pmid">8929361</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uchiyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yodoi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sagawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takatsuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Uchino</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Adult T-cell leukemia: clinical and hematologic features of 16 cases</article-title>
          <source>Blood</source>
          <year>1977</year>
          <volume>50</volume>
          <fpage>481</fpage>
          <lpage>492</lpage>
          <pub-id pub-id-type="pmid">301762</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma</article-title>
          <source>Blood</source>
          <year>1983</year>
          <volume>61</volume>
          <fpage>192</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">6600211</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poiesz</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Ruscetti</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Gazdar</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Bunn</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Minna</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma</article-title>
          <source>Proc  Natl Acad Sci USA</source>
          <year>1980</year>
          <volume>77</volume>
          <fpage>7415</fpage>
          <lpage>7419</lpage>
          <pub-id pub-id-type="pmid">6261256</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hinuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hanaoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Shirakawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miyoshi</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera</article-title>
          <source>Proc Natl  Acad Sci USA</source>
          <year>1981</year>
          <volume>78</volume>
          <fpage>6476</fpage>
          <lpage>6480</lpage>
          <pub-id pub-id-type="pmid">7031654</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seiki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takatsuki</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1984</year>
          <volume>81</volume>
          <fpage>2534</fpage>
          <lpage>2537</lpage>
          <pub-id pub-id-type="pmid">6326131</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimoyama</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984&#x2013;87)</article-title>
          <source>Br J  Haematol</source>
          <year>1991</year>
          <volume>79</volume>
          <fpage>428</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">1751370</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimoyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ota</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yunoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Konda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takatsuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ichimaru</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tominaga</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M</article-title>
          <source>J Clin Oncol</source>
          <year>1988</year>
          <volume>6</volume>
          <fpage>128</fpage>
          <lpage>141</lpage>
          <pub-id pub-id-type="pmid">2891797</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debatin</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Goldmann</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Bamford</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Krammer</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Monoclonal-antibody- mediated apoptosis in adult T cell leukaemia</article-title>
          <source>Lancet</source>
          <year>1990</year>
          <volume>335</volume>
          <fpage>497</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">1689786</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debatin</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Krammer</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia</article-title>
          <source>Blood</source>
          <year>1993</year>
          <volume>81</volume>
          <fpage>2972</fpage>
          <lpage>2977</lpage>
          <pub-id pub-id-type="pmid">7684622</pub-id>
        </citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sugahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hiragata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsuruda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tomonaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines</article-title>
          <source>Int J Cancer</source>
          <year>1997</year>
          <volume>72</volume>
          <fpage>128</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">9212233</pub-id>
        </citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirakata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsuruda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tomonaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias</article-title>
          <source>Br J Haematol</source>
          <year>1997</year>
          <volume>99</volume>
          <fpage>858</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="pmid">9432034</pub-id>
        </citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landowski</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Buyuksal</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Painter</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Dalton</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
          <article-title>Mutations in the Fas antigen in patients with multiple myeloma</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>90</volume>
          <fpage>4266</fpage>
          <lpage>4270</lpage>
          <pub-id pub-id-type="pmid">9373236</pub-id>
        </citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beltinger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kurz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bohler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schrappe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Debatin</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia</article-title>
          <source>Blood</source>
          <year>1998</year>
          <volume>91</volume>
          <fpage>3943</fpage>
          <lpage>3951</lpage>
          <pub-id pub-id-type="pmid">9573033</pub-id>
        </citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamiya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Etoh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzushima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takatsuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuoka</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells</article-title>
          <source>Blood</source>
          <year>1998</year>
          <volume>91</volume>
          <fpage>3935</fpage>
          <lpage>3942</lpage>
          <pub-id pub-id-type="pmid">9573032</pub-id>
        </citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sohda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Momita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Established IL-2-dependent double-negative (CD4&#x2212; CD8&#x2212;) TCR alpha beta/CD3+ ATL cells: induction of CD4 expression</article-title>
          <source>Br J Haematol</source>
          <year>1994</year>
          <volume>88</volume>
          <fpage>234</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="pmid">7803265</pub-id>
        </citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ohmoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamamura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tomonaga</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Features of the cytokines secreted by adult T cell leukemia (ATL) cells</article-title>
          <source>Leuk Lymphoma</source>
          <year>1996</year>
          <volume>21</volume>
          <fpage>443</fpage>
          <lpage>447</lpage>
          <pub-id pub-id-type="pmid">9172809</pub-id>
        </citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sohda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Toriya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsukazaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Momita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kusano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Amagasaki</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phenotypic diversity and prognosis of adult T-cell leukemia</article-title>
          <source>Leuk Res</source>
          <year>1992</year>
          <volume>16</volume>
          <fpage>435</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="pmid">1625468</pub-id>
        </citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sohda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Momita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jubashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mine</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma</article-title>
          <source>Leuk Res</source>
          <year>1993</year>
          <volume>17</volume>
          <fpage>157</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">8429692</pub-id>
        </citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kotani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aratake</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohtaki</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Expression of functional Fas antigen on adult T-cell leukemia</article-title>
          <source>Leuk Res</source>
          <year>1994</year>
          <volume>18</volume>
          <fpage>305</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="pmid">7513372</pub-id>
        </citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hiragata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Izumikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sugahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuruta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Atogami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases</article-title>
          <source>Intern Med</source>
          <year>1997</year>
          <volume>36</volume>
          <fpage>166</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">9144006</pub-id>
        </citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xerri</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Carbuccia</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Parc</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Birg</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas</article-title>
          <source>Am J Clin Pathol</source>
          <year>1995</year>
          <volume>104</volume>
          <fpage>424</fpage>
          <lpage>430</lpage>
          <pub-id pub-id-type="pmid">7572793</pub-id>
        </citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raghunath</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bishayee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation</article-title>
          <source>Mol Cell Biol</source>
          <year>1989</year>
          <volume>9</volume>
          <fpage>671</fpage>
          <lpage>677</lpage>
          <pub-id pub-id-type="pmid">2785240</pub-id>
        </citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kashles</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Yarden</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ullrich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schlessinger</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization</article-title>
          <source>Mol Cell Biol</source>
          <year>1991</year>
          <volume>11</volume>
          <fpage>1454</fpage>
          <lpage>1463</lpage>
          <pub-id pub-id-type="pmid">1705006</pub-id>
        </citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amaya</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Musci</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Kirschner</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in <italic>Xenopus</italic>embryos</article-title>
          <source>Cell</source>
          <year>1991</year>
          <volume>66</volume>
          <fpage>257</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="pmid">1649700</pub-id>
        </citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gunn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dell</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tseng</surname>
              <given-names>A</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor</article-title>
          <source>J Biol Chem</source>
          <year>1992</year>
          <volume>267</volume>
          <fpage>1470</fpage>
          <lpage>1476</lpage>
          <pub-id pub-id-type="pmid">1309784</pub-id>
        </citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Basilico</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mansukhani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors</article-title>
          <source>Mol Cell Biol</source>
          <year>1994</year>
          <volume>14</volume>
          <fpage>7660</fpage>
          <lpage>7669</lpage>
          <pub-id pub-id-type="pmid">7935480</pub-id>
        </citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Colbert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Escobedo</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of PDGF beta receptor signal transduction by coexpression of a truncated receptor</article-title>
          <source>Science</source>
          <year>1991</year>
          <volume>252</volume>
          <fpage>844</fpage>
          <lpage>848</lpage>
          <pub-id pub-id-type="pmid">1851331</pub-id>
        </citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banner</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>D'Arcy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Janes</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gentz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schoenfeld</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Broger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Loetscher</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lesslauer</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the soluble human 55 kd TNF receptor- human TNF beta complex: implications for TNF receptor activation</article-title>
          <source>Cell</source>
          <year>1993</year>
          <volume>73</volume>
          <fpage>431</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="pmid">8387891</pub-id>
        </citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Expression of the functional soluble form of human fas ligand in activated lymphocytes</article-title>
          <source>EMBO J</source>
          <year>1995</year>
          <volume>14</volume>
          <fpage>1129</fpage>
          <lpage>1135</lpage>
          <pub-id pub-id-type="pmid">7536672</pub-id>
        </citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kischkel</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Hellbardt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Behrmann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Germer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pawlita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krammer</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Cytotoxicity-dependent APO 1(Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor</article-title>
          <source>EMBO J</source>
          <year>1995</year>
          <volume>14</volume>
          <fpage>5579</fpage>
          <lpage>5588</lpage>
          <pub-id pub-id-type="pmid">8521815</pub-id>
        </citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsugane</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimoyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tajima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miwa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimotohno</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Multi-step carcinogenesis model for adult T-cell leukemia</article-title>
          <source>Jpn J Cancer Res</source>
          <year>1989</year>
          <volume>80</volume>
          <fpage>191</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="pmid">2498254</pub-id>
        </citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakashita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Suzushima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Asou</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takatsuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the p53 gene in adult T cell leukemia</article-title>
          <source>Blood</source>
          <year>1992</year>
          <volume>79</volume>
          <fpage>477</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="pmid">1730092</pub-id>
        </citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tomonaga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia</article-title>
          <source>Blood</source>
          <year>1995</year>
          <volume>85</volume>
          <fpage>2699</fpage>
          <lpage>2704</lpage>
          <pub-id pub-id-type="pmid">7742529</pub-id>
        </citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hatta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugawara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirakata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kamihira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia</article-title>
          <source>J Clin Oncol</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>1778</fpage>
          <lpage>1785</lpage>
          <pub-id pub-id-type="pmid">9164185</pub-id>
        </citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zornig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grzeschiczek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kowalski</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>KU</given-names>
            </name>
            <name>
              <surname>Moroy</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV</article-title>
          <source>Oncogene</source>
          <year>1995</year>
          <volume>10</volume>
          <fpage>2397</fpage>
          <lpage>2401</lpage>
          <pub-id pub-id-type="pmid">7784089</pub-id>
        </citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Hayday</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Craft</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A tumor-suppressor function for Fas (CD95) revealed in T cell&#x2013; deficient mice</article-title>
          <source>J Exp Med</source>
          <year>1996</year>
          <volume>184</volume>
          <fpage>1149</fpage>
          <lpage>1154</lpage>
          <pub-id pub-id-type="pmid">9064331</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
